Oncology Institute (NASDAQ:STLN) Stock Sale Revealed by Sen. Richard Blumenthal

Senator Richard Blumenthal (Democratic-Connecticut) recently sold part of their stake in Oncology Institute, Inc. (NASDAQ:STLN). In a filing disclosed on October 26th, the Senator disclosed that they had sold between $1,001 and $15,000 in Oncology Institute stock on September 18th.

Senator Richard Blumenthal also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/23/2026.
• Sold $15,001 – $50,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/22/2026.
• Sold $1,001 – $15,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/22/2026.
• Sold $15,001 – $50,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/18/2026.

Oncology Institute Trading Up 4.8%

Shares of NASDAQ STLN opened at $6.59 on Wednesday. Oncology Institute, Inc. has a twelve month low of $2.32 and a twelve month high of $7.13. The business has a 50 day simple moving average of $6.47.

Oncology Institute (NASDAQ:STLN) last released its earnings results on Thursday, August 6th. The company reported ($0.08) earnings per share (EPS) for the quarter. The firm had revenue of $161.28 million during the quarter, compared to the consensus estimate of $152.80 million. On average, analysts forecast that Oncology Institute, Inc. will post -0.21 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on STLN. Needham & Company LLC boosted their price objective on Oncology Institute from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, October 14th. BTIG Research upped their price objective on Oncology Institute from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Thursday, July 9th. Weiss Ratings initiated coverage on Oncology Institute in a research report on Thursday, August 6th. They set a “sell (d-)” rating for the company. Finally, Lake Street Capital initiated coverage on Oncology Institute in a research report on Monday, July 6th. They set a “buy” rating and a $10.00 target price for the company. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Oncology Institute presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

Institutional Investors Weigh In On Oncology Institute

Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in shares of Oncology Institute in the second quarter worth about $25,787,000. State Street Corp bought a new position in shares of Oncology Institute in the second quarter valued at approximately $8,432,000. Renaissance Technologies LLC boosted its position in shares of Oncology Institute by 25.1% in the first quarter. Renaissance Technologies LLC now owns 902,809 shares of the company’s stock valued at $2,772,000 after acquiring an additional 180,909 shares during the period. FourWorld Capital Management LLC grew its stake in Oncology Institute by 30.4% during the first quarter. FourWorld Capital Management LLC now owns 499,196 shares of the company’s stock valued at $1,533,000 after acquiring an additional 116,496 shares in the last quarter. Finally, Manatuck Hill Partners LLC purchased a new position in Oncology Institute during the second quarter valued at approximately $2,444,000. 36.86% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, major shareholder Jorey Chernett purchased 12,000 shares of the business’s stock in a transaction on Friday, August 14th. The stock was purchased at an average cost of $6.54 per share, with a total value of $78,480.00. Following the acquisition, the insider directly owned 10,660,858 shares in the company, valued at approximately $69,722,011.32. This trade represents a 0.11% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Brad Hively sold 298,853 shares of the firm’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $6.51, for a total transaction of $1,945,533.03. Following the completion of the transaction, the director directly owned 411,976 shares of the company’s stock, valued at approximately $2,681,963.76. The trade was a 42.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 4.40% of the company’s stock.

About Senator Blumenthal

Richard Blumenthal (Democratic Party) is a member of the U.S. Senate from Connecticut. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Blumenthal (Democratic Party, Working Families Party) ran for re-election to the U.S. Senate to represent Connecticut. He won in the general election on November 8, 2022. Before his election to the Senate, Blumenthal had served as the Connecticut Attorney General since 1991. He served in the Connecticut State Senate from 1987 to 1991 and in the Connecticut House of Representatives from 1984 to 1987. As of a 2014 analysis of multiple outside rankings, Blumenthal is one of the most reliable Democratic votes, meaning he can be considered a safe vote for the Democratic Party in Congress.

About Oncology Institute

The Oncology Institute is a value-based oncology care company focused on delivering comprehensive cancer treatment and related services through community-based care settings. Its model is designed to support patients throughout the cancer-care journey while coordinating treatment among oncologists, primary-care providers, specialists and other healthcare professionals.

The company provides medical oncology and hematology services, cancer screening and diagnosis, treatment planning, chemotherapy and other infusion therapies, supportive care, survivorship services and care-management programs.